IIFL View
Go
  • Divi's Lab.

    The regulatory overhang on Divi’s Lab has been removed after company received Establishment Inspection Report (EIR) from USFDA on its Vishakhapatnam Unit-2 facility. Its Hyderabad facility however is due for USFDA inspection anytime. While the capacit...

    Buy Reco. Price: 1,418.00

  • VST Inds.

    Volume growth for FY18 remained flat of the company due to the significant price hike of ~10% to pass on the tax increase under GST. However, company has posted ~9% volume growth for each Q1FY19 and Q2FY19 on a muted base. Encouraged by healthy volume growt...

    Buy Reco. Price: 3,019.70

  • HEG

    Steel capacity cut in China (150MT capacity shutdown during CY16-18 weakened Chinese exports) due to environmental concerns has boosted steel production across the globe to meet increasing demand. Further, preference for steel capacities based on electric a...

    Buy Reco. Price: 4,125.00

  • Power Grid Corpn

    Power Grid Corporation of India Ltd (PGCIL), a PSU power transmission company, is likely to benefit from healthy project commissioning (Rs28,000-30,000cr per annum) leading to revenue CAGR of 12.7% over FY18-20E. This revenue growth is likely to lead to PAT...

    Buy Reco. Price: 191.20

  • Sundaram Finance

    We expect SFL to report ~19% yoy AUM growth due to sector dynamics, improved focus on non-CV business (especially the CE and tractor segment) in addition to market share gains in the core CV lending business, mainly LCV portfolio. Management had guided for ...

    Buy Reco. Price: 1,419.00

  • Fortis Health.

    Fortis Healthcare (FHL) is on track to control costs and move to the asset-light model in hospitals business. FHL is planning to buy Indian healthcare assets from RHT which will save ~Rs250cr annually and improve margins. Its diagnostic business has lower m...

    Accumulate Reco. Price: 129.60

  • Natco Pharma

    Natco Pharma is expected to benefit from the launch of complex, low-competition drugs in the US market (gDoxil, gVidaza, gForsenol and gTamiflu suspension). The gCopaxone of Natco/Mylan has gained ~18% market share by end of Q1FY19. This low-competition dru...

    Buy Reco. Price: 682.80

  • Adani Ports

    APSEZ intends to commercialise its fleet of 19 dredgers in order to drive its revenue. APSEZ is expected to see improved earnings momentum owing to (a) improvement in the volumes at Mundra port, (b) strong growth in the container volumes, and (c) improved c...

    Buy Reco. Price: 311.00

  • Alembic Pharma

    Alembic (APL) is planning to launch 20-25 products in India. Further, with the commissioning of new oncology and solid dosage facilities and growth in $150mn annual US base by launching 10-12 products annually augurs well for Alembic. Hence, we expect CAGR ...

    Accumulate Reco. Price: 580.00

  • Corporation Bank

    It had got Rs2,187cr under PSU banks recapitalization programme for FY18, which will aid in providing for bad loans and maintaining regulatory capital. However, higher bad loan provisioning and rising bond yields would dent profitability over...

    Reduce Reco. Price: 23.90